The global cerebral aneurysm management market is expected to expand from US$ 1.56 billion in 2023 to US$ 2.98 billion by 2023–2033 at a cumulative annual growth rate (CAGR) of 6.7%. The market for cerebral aneurysm management is expected to grow due to the ageing population and the availability of various medications for the ailment. Between 2018 and 2022, the market for cerebral aneurysm management grew at a compound annual growth rate (CAGR) of 4%.

The growing number of people with cerebrovascular illnesses worldwide is driving the expansion of the cerebral aneurysm therapy market. Factors such as an increase in high blood pressure patients, blood vessel injuries, and harmful lifestyle behaviours such as smoking all contribute to the market’s growth. The growing use of medicinal therapy to treat unruptured cerebral aneurysms, advances in neurodegenerative disease drug development, and a rise in cigarette smokers are all factors.

Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16634

The market is being boosted by improved healthcare infrastructure, increased healthcare expenditure, and continued research and development initiatives. The market forecast for 2023 to 2033 is favourable, with prospects for development due to drug and treatment option innovations. Furthermore, due to the prevalence of geriatric population and technologically advanced healthcare infrastructure, North America and Europe are expected to be major contributors to the development of the Cerebral Aneurysm Management market.

Key Takeaways from the Market Study

• The Cerebral Aneurysm Management market is estimated to develop at a 6.7% CAGR between 2023 and 2033.
• In the Cerebral Aneurysm Management market, hospital pharmacies are estimated to retain 40% of the market share in 2023.
• In 2023, North America is estimated to have 45% of the Cerebral Aneurysm Management market.
• The Asia Pacific Cerebral Aneurysm Management Market is anticipated to account for 37% of the total market in 2023.

“Increase in technologically advanced healthcare infrastructures along with awareness of treating Cerebral aneurysm is driving the growth of the Cerebral Aneurysm Management market.” states an FMI analyst

Competitive Landscape

Key players in the Cerebral Aneurysm Management market are Biogen, Pfizer Inc, Hoffmann-La Roche Ltd, Merck Sharp & Dohme Corp, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Orion Corporation, UCB S.A., Acadia Pharmaceuticals Inc, Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation

• Sanofi, a key player in the Cerebral Aneurysm Management market is focusing on integrating technology to offer diagnostic test for treating cerebral aneurysm.
• Biogen, another key player in the Cerebral Aneurysm Management market is focusing on investing in research and development for innovating medications.

Key Segments Profiled in the Cerebral Aneurysm Management Market Survey

Drug Class:

• Antihypertensives
• Antiepileptics
• Analgesics
• Antiemetics
• Antacids

Route of Administration:

• Oral
• Injectable
• Transdermal

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy